At the molecular level, the treatment of MDA-MB-453 breast cancer cell line, OVCAR3 ovarian cancer cell line and HeLa cervical adenocarcinoma cell line with nelfinavir and the proteasome inhibitor bortezomib resulted in the upregulation of SESN2 protein. Here, SESN2 is linked to breast carcinoma.